In patients on effective cardiometabolic therapy who show clear reduction in liver fat over 12–24 months but no improvement in liver stiffness, what decision rule do you use to determine whether to escalate liver-directed evaluation or therapy (e.g., additional NITs or biopsy) versus continue current management?